These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa. Gill CM; Aktaþ E; Alfouzan W; Bourassa L; Brink A; Burnham CD; Canton R; Carmeli Y; Falcone M; Kiffer C; Marchese A; Martinez O; Pournaras S; Satlin M; Seifert H; Thabit AK; Thomson KS; Villegas MV; Nicolau DP; Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2533-2541. PubMed ID: 34291323 [TBL] [Abstract][Full Text] [Related]
8. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients. Zamudio R; Hijazi K; Joshi C; Aitken E; Oggioni MR; Gould IM Int J Antimicrob Agents; 2019 Jun; 53(6):774-780. PubMed ID: 30831233 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar. Sid Ahmed MA; Abdel Hadi H; Hassan AAI; Abu Jarir S; Al-Maslamani MA; Eltai NO; Dousa KM; Hujer AM; Sultan AA; Soderquist B; Bonomo RA; Ibrahim EB; Jass J; Omrani AS J Antimicrob Chemother; 2019 Dec; 74(12):3497-3504. PubMed ID: 31504587 [TBL] [Abstract][Full Text] [Related]
10. Ceftazidime-avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013. Sader HS; Castanheira M; Mendes RE; Flamm RK; Farrell DJ; Jones RN Antimicrob Agents Chemother; 2015; 59(6):3656-9. PubMed ID: 25845861 [TBL] [Abstract][Full Text] [Related]
11. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021). Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849 [TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections. Sader HS; Castanheira M; Duncan LR; Mendes RE Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144 [TBL] [Abstract][Full Text] [Related]
14. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer. Hachem R; Reitzel R; Rolston K; Chaftari AM; Raad I Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115350 [TBL] [Abstract][Full Text] [Related]
15. Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa. Lasarte-Monterrubio C; Fraile-Ribot PA; Vázquez-Ucha JC; Cabot G; Guijarro-Sánchez P; Alonso-García I; Rumbo-Feal S; Galán-Sánchez F; Beceiro A; Arca-Suárez J; Oliver A; Bou G J Antimicrob Chemother; 2022 Sep; 77(10):2809-2815. PubMed ID: 35904000 [TBL] [Abstract][Full Text] [Related]
16. Results from the China Antimicrobial Surveillance Network (CHINET) in 2017 of the Yin D; Wu S; Yang Y; Shi Q; Dong D; Zhu D; Hu F; Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30617091 [TBL] [Abstract][Full Text] [Related]
18. Integrated Genome-Wide Analysis of an Isogenic Pair of Huang W; Hamouche JE; Wang G; Smith M; Yin C; Dhand A; Dimitrova N; Fallon JT Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033143 [TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections. Arca-Suárez J; Lasarte-Monterrubio C; Rodiño-Janeiro BK; Cabot G; Vázquez-Ucha JC; Rodríguez-Iglesias M; Galán-Sánchez F; Beceiro A; González-Bello C; Oliver A; Bou G J Antimicrob Chemother; 2021 Jan; 76(1):91-100. PubMed ID: 33083833 [TBL] [Abstract][Full Text] [Related]
20. Potentiation of ceftazidime by avibactam against β-lactam-resistant Pseudomonas aeruginosa in an in vitro infection model. Sy SK; Zhuang L; Beaudoin ME; Kircher P; Tabosa MA; Cavalcanti NC; Grunwitz C; Pieper S; Schuck VJ; Nichols WW; Derendorf H J Antimicrob Chemother; 2017 Apr; 72(4):1109-1117. PubMed ID: 28077672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]